Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liver Cancer: early-phase trial registry
30 of 81 indexed Liver Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #172 of 28,707 conditions by registered trial count.
81 US clinical trials · 30 currently recruiting · #172 of 28,707 conditions by registered trial count
Liver Cancer: 81 US clinical trials tracked, 30 recruiting.
Liver Cancer is the subject of 81 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition liver-cancer
OPEN 30 | RECR 37% | LATE 4 | EARLY 38 | RANK #172 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Bipolar I Disorder (37% recruiting · 27 trials)
Liver Cancer lists 30 open slots (37% of 81 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liver Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liver Cancer is recruiting below its size-band peers.
30 of 81 indexed trials (37%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Liver Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 8 of 81 trials (9.9%). 54 distinct sponsors appear on at least one study for this condition label.
-
Most Liver Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 79 trials that report a genuine target (sentinel values excluded). 50 of those (63.3%) plan for fewer than 100 participants.
-
Liver Cancer research is mostly interventional.
60 interventional and 21 observational studies make up this index (74.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
81 total, page 2 of 2
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
H3 Biomedicine
NCT02834780
A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections
Memorial Sloan Kettering Cancer Center
NCT01749332
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Gradalis
NCT01061840
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
University of Michigan Rogel Cancer Center
NCT01522937
Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer
Pathfinder Therapeutics
NCT00782886
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
M.D. Anderson Cancer Center
NCT00004136
Breath Analysis Based Disease Biomarkers
Mayo Clinic
NCT04341012
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
NCT01180959
Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT
Rutgers, The State University of New Jersey
NCT00994370
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Yale University
NCT02753881
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
National Institutes of Health Clinical Center (CC)
NCT00093444
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Wake Forest University Health Sciences
NCT01185639
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
NCT00987766
Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures
Pathfinder Therapeutics
NCT01238666
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Yale University
NCT00335829
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
NCT00004248
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals
NCT03199586
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01356628
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Masonic Cancer Center, University of Minnesota
NCT01099631
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
NCT00410956
Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
Rutgers, The State University of New Jersey
NCT00949182
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
University of Chicago
NCT00003557
A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy
Indiana University
NCT03338062
Study of New Software Used During Ablations
National Institutes of Health Clinical Center (CC)
NCT01906021
Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
University of Miami
NCT00875615
Vaccine Therapy in Treating Patients With Liver Cancer
Jonsson Comprehensive Cancer Center
NCT00005629
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
Memorial Sloan Kettering Cancer Center
NCT00003923
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
National Institutes of Health Clinical Center (CC)
NCT02471313
DX-8951f in Treating Patients With Biliary Cancer
Daiichi Sankyo
NCT00005938
DX-8951f in Treating Patients With Liver Cancer
Daiichi Sankyo
NCT00004108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 22 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Liver Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liver Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liver Cancer page
81 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Liver Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Liver Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Cancer condition card totals 81 registered trials; most-linked intervention exatecan mesylate; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.